Comparative inhibition of inducible and constitutive CYPs in rat hepatic microsomes by parathion

Xenobiotica

Volumn 34, Issue 8, 2004, Pages 723-739

  Murray, M ^a   Butler, A M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE DERIVATIVE; CYTOCHROME P450; DEXAMETHASONE; PARATHION; PESTICIDE; PHENOBARBITAL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL EXPERIMENT; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INDUCTION; ENZYME KINETICS; HYDROXYLATION; IMMUNOBLOTTING; LIVER MICROSOME; NONHUMAN; OXIDATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; RAT; TOXICOKINETICS;

ANDROSTENEDIONE; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DEXAMETHASONE; ENZYME INHIBITORS; HYDROXYLATION; INSECTICIDES; KINETICS; MALE; MICROSOMES, LIVER; NADP; PARATHION; RATS; RATS, WISTAR;

ANIMALIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 8444247106     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250412331281089     Document Type: Article

References (37)

1. BENSOUSSAN, C., DELAFORGE, M. and MAKSUY, D., 1995, Particular ability of cytochromes CYP 3A to form inhibitory CYP-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochemical Pharmacology, 49, 591-602.
2. BOCKER, R. H. and GUENGERICH, F. P., 1986, Oxidation of 4-aryl- and 4-alkyl-substituted 2,6-dimethyl-3,5-bis(alkoxycarbonyl)-1,4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450. Journal of Medicinal Chemistry, 29, 1596-1603.
3. BURATTI, F. M., VOLPE, M. T., MENEGUZ, A., VITTOZZI, L. and TESTAI, E., 2003, CYP-specific bioactivation of four organophosphorothioate pesticides by human liver microsomes. Toxicology and Applied Pharmacology, 186, 143-154.
4. BUTLER, A. M. and MURRAY, M., 1993, Inhibition and inactivation of constitutive cytochromes P450 in rat liver by parathion. Molecular Pharmacology, 43, 902-908.
5. BUTLER, A. M. and MURRAY, M., 1997, Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation. Journal of Pharmacology and Experimental Therapeutics, 280, 966-973.
6. DEMATTEIS, F., 1974, Covalent binding of sulfur to microsomes and loss of cytochrome P-450 during the oxidative metabolism of several chemicals. Molecular Pharmacology, 10, 849-854.
7. FRANKLIN, M. R., 1977, Inhibition of mixed-function oxidases by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes. Pharmacology and Therapeutics A, 2, 227-245.
8. FRANKLIN, M. R., 1995, Enhanced rates of cytochrome P450 metabolic-intermediate complex formation from nonmacrolide amines in rifampicin-treated rabbit liver microsomes. Drug Metabolism and Disposition, 23, 1379-1382.
9. HOEN, P. A. C.'t., COMMANDEUR, J. N. M., VERMEULEN, N. P. E., VAN BERKEL, T. J. C. and BIJSTERBOSCH, M. K., 2000, Selective induction of cytochrome P450 3A1 by dexamethasone in cultured rat hepatocytes. Analysis with a novel reverse transcriptase-polymerase chain reaction assay. Biochemical Pharmacology, 60, 1509-1518.
10. HONKAKOSKI, P., ZELKO, I., SUEYOSHI, T. and NEGISHI, M., 1998, The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B6 gene. Molecular and Cellular Biology, 18, 5652-5658.
11. HURH, E., LEE, E., LEE, A., KIM, Y., KIM, S., KIM, S. and LEE, M., 2000, Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. Biopharmaceutics and Drug Disposition, 21, 193-204.
12. JEFCOATE, C. R., 1978, Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical difference spectroscopy. Methods in Enzymology, 52, 258-279.
13. KLIEWER, S. A., MOORE, J. T., WADE, L., STAUDINGER, J. L., WATSON, M. A., JONES, S. A., McKEE, D. D., OLIVER, B. B., WILLSON, T. M., ZETTERSTROM, R. H., PERLMANN, T. and LEHMANN, J. M., 1998, An orphan nuclear receptor activated by pregnanes defines a novel steroid signalling pathway. Cell, 92, 73-82.
14. LAEMMLI, U. K., 1970, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685.
15. LIN, H. L., ZHANG, H., WASKELL, L. and HOLLENBERG, P. F., 2003, Threonine-205 in the F helix of P450 2B1 contributes to androgen 16β-hydroxylation activity and mechanism-based inactivation. Journal of Pharmacology and Experimental Therapeutics, 306, 744-751.
16. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
17. MAHNKE, A., STROTKAMP, D., Roos, P. H., HANSTEIN, W. G., CHABOT, G. G. and NEF, P., 1997, Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver. Archives of Biochemistry and Biophysics, 337, 62-68.
18. MARTINI, R., BUTLER, A. M., JIANG, X.-M. and MURRAY, M., 1995, Pretranslational down regulation of cytochrome P450 2C11 in vitamin A-deficient male rat liver: prevention by dietary inclusion of retinoic acid. Journal of Pharmacology and Experimental Therapeutics, 273, 427-434.
19. MCNEIL, C. M. and MURRAY, M., 1996, Inhibition of microsomal cytochromes P450 in rat liver by the tricyclic antidepressant drug desipramine and its primary oxidized metabolites. Biochemical Pharmacology, 51, 15-20.
20. MUAKKASAH, S. F., BIDLACK, W. R. and YANG, W. C. T., 1981, Mechanism of the inhibitory action of isoniazid on microsomal drug metabolism. Biochemical Pharmacology, 30, 1651-1658.
21. MURRAY, M., 1988, Complexation of cytochrome P450 isozymes in hepatic microsomes from SKF-525-A-induced rats. Archives of Biochemistry and Biophysics, 262, 381-388.
22. MURRAY, M., 1992, Metabolite intermediate complexation of microsomal cytochrome CYP 2C11 in male rat liver by nortriptyline. Molecular Pharmacology, 42, 931-938.
23. MURRAY, M. and BUTLER, A. M., 1995, Identification of a reversible component in the in vitro inhibition of rat hepatic cytochrome P450 2B1 by parathion. Journal of Pharmacology and Experimental Therapeutics, 272, 639-644.
24. MURRAY, M. and MURRAY, K., 2003, Mechanism-based inhibition of CYP activities in rat liver by fluoxetine and structurally similar alkylamines. Xenobiotica, 33, 973-987.
25. MURRAY, M., SEFTON, R. M., MARTINI, R. and BUTLER, A. M., 1999, Comparative induction of CYP3A and CYP2B in rat liver by 3-benzoylpyridine and meyrapone. Chemico-Biological Interactions, 113, 161-173.
26. NORMAN, B. J., POORE, R. E. and NEAL, R. A., 1974, Studies of the binding of sulfur released in the mixed-function oxidase-catalyzed metabolism of diethyl p-nitrophenyl phosphorothioate (parathion) to diethyl p-nitrophenyl phosphate (paraoxon). Biochemical Pharmacology, 23, 1733-1744.
27. OMURA, T. and SATO, R., 1964, The carbon monoxide binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370-2378.
28. ORTIZ DE MONTELLANO, P. R. and MICO, B. A., 1980, Destruction of cytochrome P-450 by ethylene and other olefins. Molecular Pharmacology, 18, 128-135.
29. REIDY, G. F., MEHTA, I. and MURRAY, M., 1989, Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. Molecular Pharmacology, 35, 736-743.
30. REIN, H., RISTAU, O., MISSELWITZ, R., BUDER, E. and RUCKPAUL, K., 1979, The importance of the spin equilibrium in cytochrome P-450 for the reduction rate of the heme iron. Acta Biologica et Medica Germanica, 38, 187-199.
31. ROBERTS, E. S., HOPKINS, N. E., ALWORTH, W. L. and HOLLENBERG, P. F., 1993, Mechanism-based inactivation of cytochrome P450 2B1 by 2-ethynylnaphthalene: identification of an active-site peptide. Chemical Research in Toxicology, 6, 38-45.
32. SEGEL, I., 1975, in Enzyme Kinetics: Behaviour and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems (New York: Wiley), pp. 100-226.
33. SULTATOS, L. G., 1986, The effects of phenobarbital pretreatment on the metabolism and acute toxicity of the pesticide parathion in the mouse. Toxicology and Applied Pharmacology, 86, 105-111.
34. SUTTON, D., BUTLER, A. M., NADIN, L. and MURRAY, M., 1997, Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYT3A4 activity by oxidized diltiazem metabolites. Journal of Pharmacology and Experimental Therapeutics, 282, 294-300.
35. TRIEU, L. and MURRAY, M., 2000, Metabolite-intermediate complexation and inhibition of microsomal CYP3A in rat liver by diltiazem. Xenobiotica, 30, 131-140.
36. VON WACHENFELDT, C. and JOHNSON, E. F., 1995, Structures of eukaryotic cytochrome P450 enzymes. In P. P. Ortiz de Montellano (ed.), Cytochrome P450: Structure, Mechanism, and Biochemistry, 2nd edn (New York: Plenum), pp. 183-223.
37. WAXMAN, D. J., KO, A. and WALSH, C., 1983, Regioselectivity and stereoselectivity of androgen hydroxylations catalysed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. Journal of Biological Chemistry, 258, 11937-11947.